Tirzepatide overview
Dual GLP-1/GIP receptor agonist. Brand names: Mounjaro (T2D), Zepbound (chronic weight management; OSA in adults with obesity).
Tirzepatide at a glance
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
Tirzepatide is the active ingredient in two FDA-approved brands: Zepbound for weight management and sleep apnea in adults (Zepbound label) and Mounjaro for type 2 diabetes in adults and children 10 and older (Mounjaro label). In SURMOUNT-1 (NEJM 2022), the 15 mg dose produced 20.9% average weight loss at 72 weeks under the treatment-regimen estimand, and in SURMOUNT-5 (NEJM 2025) tirzepatide produced 20.2% versus 13.7% with semaglutide. Compounded tirzepatide is not FDA-approved and was not tested in these trials, as FDA’s page on unapproved GLP-1 drugs explains.